Frontiers in Immunology (Jul 2021)
Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities
- Yifan Xu,
- Yifan Xu,
- Jin Jiang,
- Yutong Wang,
- Yutong Wang,
- Wei Wang,
- Haokun Li,
- Haokun Li,
- Wenyu Lai,
- Wenyu Lai,
- Zhipeng Zhou,
- Zhipeng Zhou,
- Wei Zhu,
- Zheng Xiang,
- Zhiming Wang,
- Zhe Zhu,
- Lingfeng Yu,
- Xiaolan Huang,
- Hua Zheng,
- Sha Wu,
- Sha Wu
Affiliations
- Yifan Xu
- Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China
- Yifan Xu
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
- Jin Jiang
- Guangzhou Blood Center, Department of Blood Source Management, Guangzhou, China
- Yutong Wang
- Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China
- Yutong Wang
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
- Wei Wang
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Haokun Li
- Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China
- Haokun Li
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
- Wenyu Lai
- Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China
- Wenyu Lai
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
- Zhipeng Zhou
- Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China
- Zhipeng Zhou
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
- Wei Zhu
- Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Zheng Xiang
- Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
- Zhiming Wang
- State Key Laboratory of Esophageal Cancer Prevention & Treatment, Sino-British Research Center for Molecular Oncology, National Center for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China
- Zhe Zhu
- Huikezhe Biological Tech. Beijing, R&D Department, Beijing, China
- Lingfeng Yu
- School of Basic Medicine Science, Tianjin Medical University, Tianjin, China
- Xiaolan Huang
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- Hua Zheng
- 0Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- Sha Wu
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
- Sha Wu
- 1National Demonstration Center for Experimental Education of Basic Medical Sciences, Southern Medical University, Guangzhou, China
- DOI
- https://doi.org/10.3389/fimmu.2021.725330
- Journal volume & issue
-
Vol. 12
Abstract
Gynecologic malignancies, mainly including ovarian cancer, cervical cancer and endometrial cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells redirected by genes which encode for tumor-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs) has demonstrated a delightful potency in B cell lymphoma treatment. Researches impelling ACT to be applied in treating solid tumors like gynecologic tumors are ongoing. This review summarizes the preclinical research and clinical application of engineered T cells therapy for gynecologic cancer in order to arouse new thoughts for remedies of this disease.
Keywords
